Cancer Immunology, Immunotherapy

Overview

Cancer Immunology, Immunotherapy is providing a timely and open access publication of original discovery and developments in basic and translational research in the field of cancer immunology and immunotherapy.

Editor-in-Chief

Haidong Dong

Journal Impact Factor: 4.6 (2023)

5-year Journal Impact Factor: 5.4 (2023)

Submission to first decision (median): 4 days

Downloads: 1,142,964 (2023)

Societies and partnerships

Latest articles

Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era
Allison L. Gradone
Vincent T. Ma
Christopher D. Lao
Brief Report Open access 05 October 2024 Article: 259
Part of 1 collection:

Adverse Drug Reactions in Immunotherapy: Safety and Management
Integrative analyses of bulk and single-cell RNA-seq reveals the correlation between SPP1⁺ macrophages and resistance to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma
Zhenyang Geng
Feng Li
Yu Qi
Research Open access 05 October 2024 Article: 257
Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model
Tetsuro Tachi
Noriyuki Kijima
Naoki Hosen
Research Open access 05 October 2024 Article: 256
PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis
Jens Blobner
Laura Dengler
Louisa von Baumgarten
Research Open access 03 October 2024 Article: 255
PD-L1⁺ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC
Xiaoyu Sun
Yaoqi Gui
Bo Wang
Research Open access 03 October 2024 Article: 254

View all articles

Journal updates

Cancer Immunology, Immunotherapy is now fully open access!

We are excited to announce that Cancer Immunology, Immunotherapy has now become a fully open-access (OA) journal as of 5^th January 2024. This means that we will only be publishing articles as Open Access meaning content will be freely available to readers worldwide, enabling the widest possible dissemination and reuse.
Springer Nature Oncology Webinar Series

Sign up for free online attendance.
Learn more about Springer Nature’s oncology titles

Discover the range of academic oncology titles at Springer Nature here.
Announcing new Editor-in-Chief: Dr. Haidong Dong

The journal is pleased to announce Dr. Haidong Dong has been named the new Editor-in-Chief of Cancer Immunology, Immunotherapy, effective January 1, 2020.

View all updates

Journal information

Electronic ISSN: 1432-0851
Print ISSN: 0340-7004
Abstracted and indexed in: AGRICOLA

BFI List

BIOSIS

Baidu

Biological Abstracts

CLOCKSS

CNKI

CNPIEC

Chemical Abstracts Service (CAS)

Current Contents/Life Sciences

Dimensions

EBSCO

EMBASE

Google Scholar

Japanese Science and Technology Agency (JST)

Medline

Naver

Norwegian Register for Scientific Journals and Series

OCLC WorldCat Discovery Service

Pathway Studio

Portico

ProQuest

PubMedCentral

Reaxys

SCImago

SCOPUS

Science Citation Index Expanded (SCIE)

Semantic Scholar

TD Net Discovery Service

UGC-CARE List (India)

Wanfang